PT - JOURNAL ARTICLE AU - Perkins, Griffith B. AU - Hope, Christopher M. AU - Chai, Cheng Sheng AU - Tunbridge, Matthew J. AU - Sterling, Sebastian AU - Webb, Kevin AU - Yap, Joey AU - Yeow, Arthur Eng Lip AU - Masavuli, Makutiro G. AU - Kireta, Svjetlana AU - Zuiani, James D. AU - Akerman, Anouschka AU - Aggarwal, Anupriya AU - Milogiannakis, Vanessa AU - Roberts, Matthew B. AU - Wilson, William AU - Hurtado, Plinio R. AU - Turville, Stuart AU - Grubor-Bauk, Branka AU - Barry, Simon C. AU - Coates, P. Toby AU - Ravindran, Janakan AU - Hissaria, Pravin TI - Immune profiling of COVID-19 vaccine responses in people with multiple sclerosis on B cell-depleting therapy AID - 10.1101/2023.12.04.23299409 DP - 2023 Jan 01 TA - medRxiv PG - 2023.12.04.23299409 4099 - http://medrxiv.org/content/early/2023/12/05/2023.12.04.23299409.short 4100 - http://medrxiv.org/content/early/2023/12/05/2023.12.04.23299409.full AB - Background and Objective People with multiple sclerosis (pwMS) receiving B cell-depleting therapies have impaired antibody responses to vaccination. In a proportion of individuals, repeat vaccination against COVID-19 leads to seroconversion. We sought to describe the immune phenotype of pwMS on ocrelizumab, and identify clinical and immunological determinants of an effective vaccine response.Methods This was a single-centre, prospective cohort study. Peripheral blood samples were collected from pwMS receiving ocrelizumab (n = 38) pre and post administration of a third dose of mRNA COVID-19 vaccine. Immunogenicity was measured by T cell IFNγ ELISpot, antibody titres, and live virus neutralisation. Humoral immunity was benchmarked against pwMS receiving natalizumab (n = 15), and against a correlate of real-world protection (50% reduction in incidence of infection) from SARS-CoV-2 ancestral and omicron BA.5 variants. The peripheral immune phenotype was comprehensively assessed by flow cytometry, and potential clinical and phenotypic determinants of response to vaccination identified.Results Immune cell populations relevant to disease and vaccine response were altered in pwMS receiving ocrelizumab versus natalizumab treatment, including depleted CD20-expressing B cell, T cell and NK cell populations, and elevated CD27+CD38+ T cell and ‘NK8’ cell frequencies. Following a third vaccine dose, 51% of pwMS on ocrelizumab were seropositive for SARS-CoV-2 receptor-binding-domain IgG, and 25% and 14% met the threshold for effective neutralisation of live SARS-CoV-2 ancestral and omicron BA.5 virus, respectively. B cell frequency at the time of vaccination, but not time since ocrelizumab infusion, was positively correlated with antibody response, while a strong negative correlation was observed between CD56bright NK cell frequency and antibody response in the ocrelizumab group. In this exploratory cohort, CD3−CD20+ B cells (% of lymphocytes; OR=3.92) and CD56bright NK cells (% of NK cells; OR=0.94) were predictive of an effective neutralising antibody response in second dose non-responders (AUC: 0.98).Discussion Ocrelizumab treatment was associated with an altered immune phenotype, including recently described T cell and NK populations with potential roles in disease pathogenesis. However, seroconversion was severely impaired by ocrelizumab, and less than half of those who seroconverted following a third vaccine dose demonstrated effective immunity against SARS-CoV-2 ancestral or omicron BA.5. B cell frequency was associated with an effective antibody response, while immunomodulatory CD56bright NK cells were identified as a potential negative determinant of response in those with inadequate B cell numbers. Immune phenotype rather than time since ocrelizumab infusion may help to stratify individuals for prophylaxis.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialACTRN12623001249640Funding StatementThis work has received funding from The Hospital Research Foundation Group (outside of structured grant round) and the Health Services Charitable Gifts Board (HSCGB; project grant, 70-05-52-05-20). GBP and MJT received support from the Mary Overton Research Fellowship (HSCGB) and Jacquot Research Scholarship (Royal Australasian College of Physicians), respectively.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the Central Adelaide Local Health Network Human Research Ethics Committee.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesPhenotype and correlation data are available as a network (SIF) file, and raw values can be obtained by contacting G.B.P.